1. Home
  2. KRNY vs GYRE Comparison

KRNY vs GYRE Comparison

Compare KRNY & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kearny Financial Corp

KRNY

Kearny Financial Corp

HOLD

Current Price

$8.57

Market Cap

526.7M

Sector

Finance

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$5.95

Market Cap

573.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRNY
GYRE
Founded
1884
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
526.7M
573.4M
IPO Year
2014
2004

Fundamental Metrics

Financial Performance
Metric
KRNY
GYRE
Price
$8.57
$5.95
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$9.25
$17.00
AVG Volume (30 Days)
297.8K
88.0K
Earning Date
04-23-2026
05-08-2026
Dividend Yield
5.45%
N/A
EPS Growth
130.22
N/A
EPS
0.46
N/A
Revenue
$2,580,000.00
$275,000.00
Revenue This Year
$3.89
$19.88
Revenue Next Year
$17.52
N/A
P/E Ratio
$18.78
N/A
Revenue Growth
36.00
N/A
52 Week Low
$5.76
$5.44
52 Week High
$8.67
$9.42

Technical Indicators

Market Signals
Indicator
KRNY
GYRE
Relative Strength Index (RSI) 62.47 44.61
Support Level $7.77 $5.44
Resistance Level N/A $8.13
Average True Range (ATR) 0.17 0.32
MACD 0.04 0.07
Stochastic Oscillator 74.68 54.92

Price Performance

Historical Comparison
KRNY
GYRE

About KRNY Kearny Financial Corp

Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: